Azidus Brasil: COVID-19 trials

The registry lists 10 COVID-19 studies with Azidus Brasil as lead sponsor. 1 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 1Phase 2 5Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and InfluenzaNot yet recruitingNCT06817096Phase 3
• Safety and Immunogenicity of the RNA MCTI CIMATEC HDT VaccineStatus unknownNCT05542693Phase 2
• Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 PatientsWithdrawnNCT04441398Phase 2/3
• Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19WithdrawnNCT04435314Phase 2
• Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19Status unknownNCT04423861Phase 3
• Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 PatientsStatus unknownNCT04352465Phase 1/2
• Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19SuspendedNCT04348474Early Phase 1
• Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19CompletedNCT04348409Not applicable
• Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19SuspendedNCT04329572Early Phase 1
• NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 PneumoniaCompletedNCT04315987Phase 2